The 3 Best Big Pharma Dividend Stocks of the Past 10 Years

Big pharma's been in a funk over the recent past with the patent cliff and the recession, but these three stocks have delivered for investors.

Jun 13, 2014 at 6:00PM

Big pharma's best stocks have had myriad troubles over the past decade. Patent expirations of top-selling drugs have cut away at top lines of the biggest names in the business, and tightening hospital budgets in the aftermath of the recession haven't helped. Despite the downbeat atmosphere, however, three of big pharma's biggest names have made the most of the last 10 years.

No big pharma stock's risen like Novo Nordisk (NYSE:NVO) over the last decade. Novo has focused in on treating diabetes, one of the world's biggest public health issues -- particularly in emerging markets, where Novo Nordisk has done a great job establishing itself as one of the top drug sellers. That dominance in the diabetes market and in developing economies, along with other factors, has helped Novo emerge as the top big pharma stock of the last decade.

But Novo's not the only stock capitalizing despite the recession and the patent cliff. In the video below, Motley Fool contributor Dan Carroll takes you through three of big pharma's best stocks over the past 10 years, including Novo, and whether these three picks can keep up their runs into the future.

Top dividend stocks for the next decade
The smartest investors know that dividend stocks simply crush their non-dividend paying counterparts over the long term. That's beyond dispute. They also know that a well-constructed dividend portfolio creates wealth steadily, while still allowing you to sleep like a baby. Knowing how valuable such a portfolio might be, our top analysts put together a report on a group of high-yielding stocks that should be in any income investor's portfolio. To see our free report on these stocks, just click here now.

Dan Carroll has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

A Financial Plan on an Index Card

Keeping it simple.

Aug 7, 2015 at 11:26AM

Two years ago, University of Chicago professor Harold Pollack wrote his entire financial plan on an index card.

It blew up. People loved the idea. Financial advice is often intentionally complicated. Obscurity lets advisors charge higher fees. But the most important parts are painfully simple. Here's how Pollack put it:

The card came out of chat I had regarding what I view as the financial industry's basic dilemma: The best investment advice fits on an index card. A commenter asked for the actual index card. Although I was originally speaking in metaphor, I grabbed a pen and one of my daughter's note cards, scribbled this out in maybe three minutes, snapped a picture with my iPhone, and the rest was history.

More advisors and investors caught onto the idea and started writing their own financial plans on a single index card.

I love the exercise, because it makes you think about what's important and forces you to be succinct.

So, here's my index-card financial plan:


Everything else is details. 

Something big just happened

I don't know about you, but I always pay attention when one of the best growth investors in the world gives me a stock tip. Motley Fool co-founder David Gardner (whose growth-stock newsletter was rated #1 in the world by The Wall Street Journal)* and his brother, Motley Fool CEO Tom Gardner, just revealed two brand new stock recommendations moments ago. Together, they've tripled the stock market's return over 12+ years. And while timing isn't everything, the history of Tom and David's stock picks shows that it pays to get in early on their ideas.

Click here to be among the first people to hear about David and Tom's newest stock recommendations.

*"Look Who's on Top Now" appeared in The Wall Street Journal which references Hulbert's rankings of the best performing stock picking newsletters over a 5-year period from 2008-2013.

Compare Brokers